Top Page
Australian Clinical Labs Ltd
(Sydney:ACL)
Australian Clinical Labs Ltd (ACL) vs. S&P 500 (SPY)
Australian Clinical Labs Ltd Business Overview & Revenue Model
Australian Clinical Labs Ltd Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 689.73M | 692.10M | 989.30M | 641.31M | 487.53M | Gross Profit |
| 247.36M | 566.02M | 781.71M | 521.73M | 85.04M | EBIT |
| 56.91M | 51.85M | 256.24M | 97.59M | 15.53M | EBITDA |
| 169.65M | 184.93M | 372.75M | 196.67M | 116.30M | Net Income Common Stockholders |
| 23.93M | 35.90M | 178.24M | 60.37M | 41.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 26.84M | 19.95M | 26.37M | 35.23M | 35.28M | Total Assets |
| 593.06M | 578.91M | 628.04M | 474.70M | 366.05M | Total Debt |
| 308.90M | 316.32M | 262.38M | 294.26M | 221.21M | Net Debt |
| 282.76M | 296.36M | 236.00M | 259.03M | 186.36M | Total Liabilities |
| 415.30M | 406.24M | 395.49M | 392.79M | 297.06M | Stockholders Equity |
| 177.53M | 172.42M | 232.44M | 81.90M | 68.99M |
| Cash Flow | Free Cash Flow | |||
| 153.09M | 136.75M | 262.83M | 144.36M | 92.36M | Operating Cash Flow |
| 159.59M | 143.68M | 284.09M | 153.86M | 101.74M | Investing Cash Flow |
| -7.25M | -12.18M | -72.04M | -6.08M | -9.96M | Financing Cash Flow |
| -146.14M | -137.88M | -220.91M | -147.37M | -60.92M |
Australian Clinical Labs Ltd Technical Analysis
Australian Clinical Labs Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$12.56B | 22.85 | 6.86% | 3.99% | 10.15% | 6.20% | |
68 Neutral | AU$624.76M | 20.53 | 18.39% | 3.96% | 7.80% | 99.87% | |
58 Neutral | AU$953.42M | 105.35 | 1.14% | 2.27% | 7.83% | ― | |
55 Neutral | $7.88B | 963.20 | 0.52% | 2.40% | 7.25% | -99.04% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.50% | |
50 Neutral | €838.68M | ― | -4.46% | ― | -7.82% | 98.08% |
Australian Clinical Labs Ltd Corporate Events
Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Regal Funds Management Pty Limited and its associates now holding a significant interest. This change in voting power indicates a shift in shareholder dynamics, potentially impacting the company’s strategic decisions and market positioning.
Australian Clinical Labs Ltd announced an update on their ongoing share buy-back program, revealing that a total of 4,442,629 ordinary fully paid securities have been bought back to date. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and stakeholder interests.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of the latest notification, the company has bought back a total of 4,274,630 securities, with 150,000 purchased on the previous day. This buy-back initiative may impact the company’s stock value and shareholder equity, reflecting a strategic move to manage capital and potentially enhance shareholder returns.
Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program. The company reported that it bought back 146,130 ordinary fully paid securities on the previous day, adding to a total of 3,978,500 securities bought back prior to that. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Ltd has announced a daily update on its ongoing on-market buy-back program. The company has repurchased a total of 3,978,500 ordinary fully paid securities, with 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Limited announced the cessation of Michael Thomas Alscher as a director, effective April 30, 2025. Alscher, who held interests in 280,502 ordinary shares through XYZ Services Pty Limited as trustee for the 3C Trust, will no longer be part of the company’s board. This change in directorship might impact the company’s governance and strategic direction, potentially affecting stakeholders and market perception.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, with a total of 3,678,500 ordinary fully paid securities bought back before the previous day and an additional 150,000 securities acquired on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of April 29, 2025, the company has repurchased a total of 3,678,500 ordinary fully paid securities, including 224,731 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Limited has announced a significant development involving Mitsubishi UFJ Financial Group, Inc., which has acquired a substantial holding in the company. This acquisition gives Mitsubishi UFJ Financial Group a 5.01% voting power in Australian Clinical Labs, potentially influencing the company’s governance and strategic decisions. The involvement of a major financial entity like Mitsubishi UFJ Financial Group could impact the company’s market positioning and stakeholder interests.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported that it bought back a total of 21,950 ordinary fully paid securities on the previous day, adding to the cumulative total of 3,431,819 securities repurchased. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Limited as of April 24, 2025. This change in shareholding, involving multiple transactions of ordinary shares controlled by Morgan Stanley, could impact the company’s market dynamics and investor relations, reflecting a shift in stakeholder interests.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities, with a total of 3,265,125 securities bought back before the previous day and an additional 166,694 securities acquired on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting a proactive approach to optimizing financial performance and market positioning.
Australian Clinical Labs Limited announced the retirement of its board chair, Mr. Michael Alscher, effective April 30, 2025. Mr. Alscher has been with ACL since 2015, and the company expressed gratitude for his leadership. Mr. Mark Haberlin, currently the Chair of ACL’s Audit and Risk Committee, will serve as Interim Chair. This transition is part of ACL’s succession planning to ensure the board’s composition aligns with its strategic goals. The change in leadership is expected to support ACL’s ongoing strategy and operations, potentially impacting its industry positioning and stakeholder relations.
Australian Clinical Labs Ltd has experienced a change in the interests of its substantial holder, involving entities associated with KKR. The KKR Entities have increased their voting power in the company from 5.05% to 6.06%, indicating a stronger influence in the company’s decision-making process. This change could impact the company’s operations and strategic direction, potentially affecting its market positioning and stakeholder interests.
Australian Clinical Labs Limited has announced a change in the address of its share registry office in Sydney, effective from April 14, 2025. The move to a new location at Liberty Place, Castlereagh Street, aims to streamline operations, although telephone numbers and postal addresses remain unchanged. This change reflects ACL’s ongoing efforts to optimize its operational infrastructure, potentially impacting its stakeholders by enhancing service efficiency and accessibility.
Superannuation and Investments HoldCo Pty Ltd has resubmitted a corrected Change in Substantial Holding Form for Australian Clinical Labs Ltd due to minor dependencies discovered in the initial submission. The updated form indicates an increase in voting power from 5.05% to 6.06%, reflecting a significant change in the company’s shareholder structure, which could impact its governance and strategic decisions.
Australian Clinical Labs Ltd has experienced a change in the interests of a substantial holder, Superannuation and Investments HoldCo Pty Ltd. The voting power of this substantial holder has decreased from 10.10% to 6.06%, indicating a significant reduction in their stake in the company. This change may impact the company’s shareholder dynamics and influence its market positioning.
Mitsubishi UFJ Financial Group, Inc. has become a substantial holder in Australian Clinical Labs Ltd, acquiring a significant voting power of 5.06% through various associates. This acquisition indicates a strategic move by Mitsubishi UFJ Financial Group to strengthen its influence within the company, potentially impacting the company’s future decisions and market positioning.
Australian Clinical Labs Ltd has announced that First Sentier Investors RQI Pty Ltd, a subsidiary of Mitsubishi UFJ Financial Group, has become a substantial holder in the company as of April 7, 2025. This development signifies a notable shift in the ownership structure, potentially impacting the company’s strategic direction and stakeholder interests, as First Sentier Investors now holds significant voting power in the company.
Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Australian Clinical Labs Ltd from 5.01% to 6.49% as of April 4, 2025. This change in substantial holding indicates a strengthened position for Allan Gray Australia in the company, potentially impacting its influence on corporate decisions and signaling confidence in the company’s future prospects.
Australian Clinical Labs Ltd announced the cessation of 164,164 ordinary fully paid securities due to an on-market buy-back. This move is part of the company’s capital management strategy, potentially impacting its market positioning by optimizing its capital structure and possibly enhancing shareholder value.
Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Ltd as of early April 2025. This change in substantial holding, involving transactions with entities controlled by Morgan Stanley and First Sentier Investors Holdings Pty Ltd, may impact the company’s shareholder structure and influence its market dynamics.
Mitsubishi UFJ Financial Group, Inc. has acquired a substantial holding in Australian Clinical Labs Ltd, with a voting power of over 20% in Morgan Stanley and 100% in First Sentier Investors Holdings Pty Limited. This acquisition involves a significant number of fully paid ordinary shares, indicating a strategic move that could impact the company’s market positioning and influence its future operations.
Australian Clinical Labs Ltd has announced a substantial holding by Mitsubishi UFJ Financial Group (MUFG) through its subsidiary, First Sentier Investors Holdings Pty Limited. This development signifies a notable shift in the company’s shareholder structure, potentially impacting its market positioning and stakeholder interests, as MUFG now holds significant voting power in the company.
Australian Clinical Labs Limited has announced an update regarding its ongoing share buy-back program. The company reported that it bought back 15,138 ordinary fully paid securities on the previous day, adding to a total of 3,249,987 securities repurchased to date. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities, with a total of 71,984 securities bought back on the previous day. This buy-back initiative, which began on August 29, 2024, is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Limited announced the cessation of 212,245 ordinary fully paid securities due to an on-market buy-back as of March 24, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and signaling a focus on optimizing shareholder returns.
Australian Clinical Labs Ltd announced an update on their ongoing share buy-back program, with a total of 2,900,981 securities bought back before the previous day and an additional 200,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and stakeholder interests.
Allan Gray Australia Pty Ltd has become a substantial holder in Australian Clinical Labs Limited, acquiring a 5.01% voting power through ordinary shares. This development indicates a significant investment interest in the company, potentially impacting its market positioning and signaling confidence in its future prospects.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of March 12, 2025, the company has bought back a total of 2,888,736 securities, indicating a strategic move to potentially enhance shareholder value and optimize capital structure.
Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Limited as of March 10, 2025. This change in substantial holding, primarily due to the purchase of securities by an entity controlled by Morgan Stanley, may impact the company’s shareholder structure and influence its market dynamics.
Australian Clinical Labs Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities, with a total of 141,378 securities bought back on the previous day. This buy-back initiative reflects the company’s strategic move to optimize its capital structure, potentially enhancing shareholder value and indicating confidence in its financial health.
Australian Clinical Labs Ltd has announced a change in its substantial holding status. The company has ceased to be a substantial holder as of March 6, 2025, impacting its voting securities and associations with other entities. This change could influence the company’s market position and stakeholder relationships.
Australian Clinical Labs Limited has announced the cessation of 1,200,000 ordinary fully paid securities due to an on-market buy-back, effective March 4, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and market perception, while reflecting a commitment to optimizing shareholder value.
Australian Clinical Labs Limited has announced a change in its substantial holders, with Wilson Asset Management Group acquiring a significant interest in the company. This acquisition indicates a shift in the company’s shareholder structure, potentially impacting its strategic direction and market positioning.
Australian Clinical Labs Limited announced the issuance of 16,245 ordinary fully paid securities, indicating a strategic move to enhance its equity structure. This development may impact the company’s financial positioning and shareholder value, reflecting its ongoing efforts to strengthen its market presence.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program. As of March 3, 2025, the company has bought back a total of 2,475,483 ordinary fully paid securities, including 200,000 on the previous day. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure.
Australian Clinical Labs Limited has reaffirmed its financial guidance for FY25, maintaining its revenue projection between $725 million and $752 million, and underlying EBIT between $65 million and $73 million. The company has consistently aligned its guidance with market expectations, as confirmed by sell-side analyst reports, and does not anticipate any material impact on its share price from its recent half-year results announcement.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. The company reported the buy-back of 17,287 ordinary fully paid securities on the previous day, adding to a total of 2,258,196 securities bought back to date. This buy-back initiative reflects the company’s strategy to manage its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Ltd has announced an update regarding its ongoing share buy-back program. As of February 27, 2025, the company has repurchased a total of 1,258,196 ordinary fully paid securities, with an additional 1,000,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Australian Clinical Labs Ltd announced a dividend distribution of AUD 0.035 per share for the period ending December 31, 2024. The ex-dividend date is set for March 27, 2025, with the record date on March 28, 2025, and payment to be made on April 16, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders.
Australian Clinical Labs Limited announced its financial results for the first half of the fiscal year 2025, reporting a 9.5% revenue growth and a 9.7% increase in MBS revenue, resulting in an underlying EBIT of $27.3 million. The company reaffirmed its FY25 guidance of $65 million to $73 million and declared a 3.5 cents per share fully franked interim dividend. ACL’s statutory EBIT rose to $26.9 million, up $11.0 million from the previous year, with a statutory NPAT of $11.8 million, reflecting a $6.8 million increase. The company continues its on-market buy-back program, indicating a strong financial performance and commitment to returning value to shareholders.
Australian Clinical Labs announced its financial results for the half-year ended December 31, 2024, reporting a 9.46% increase in total revenue to $369.2 million. The company’s profit attributable to members surged by 136.03% to $11.7 million, reflecting strong operational performance. The interim dividend was increased to 3.50 cents per share, fully franked, indicating confidence in future growth. These results highlight ACL’s robust market positioning and its commitment to delivering value to stakeholders.
Australian Clinical Labs Limited will announce its financial and operating results for the half-year ending December 31, 2024, on February 26, 2025. The results will be discussed in a webinar hosted by CEO Melinda McGrath and CFO Matthew Cordingley, offering stakeholders insights into the company’s performance and future outlook.